《新股消息》醫渡科技(02158.HK)公開超購近1,633倍及上限定價 一手中籤率20%
醫渡科技(02158.HK)公布招股結果,公布計劃全球發售1.56億股原定10%於本港公開發售,公開發售錄超購1,632.84倍,經重新分配後,公開發售股數增至50%,國際發售項下初步提呈發售的發售股份已獲大量超額認購,相當於國際發售項下初步可供認購發售股份總數的約33.4倍。
每股發售價定於26.3元,為上限定價(招股價介乎23.5元至26.3元),一手100股中籤率為20%。該股將於明日(15日)掛牌上市。聯席保薦人為高盛及中金公司。
公司預計,上市集資淨額為39.02億元,其中35%擬用於加強數據處理技術及機器學習算法等核心能力,及提升提供客戶所需解決方案的能力;35%擬用於為業務運營提供資金及進一步進行業務擴張,包括為現有及新市場開發新的應用和解決方案以及在現有或新市場中銷售及營銷該等新應用程序及解決方案;20%擬用於通過戰略合夥、投資及收購以進一步豐富生態系統;以及10%擬用於營運資金及一般企業用途。
公司引入八名基石投資者,包括OrbiMed Funds、加拿大退休金計劃投資委員會及文萊投資局旗下Yaqut Sdn Bhd、騰訊(00700.HK)附屬Tencent Mobility、嘉里控股旗下Velmar Company Limited、Matthews Funds、3W Fund Management及中國東方等,合共認購6,188.62萬股股份,佔全球發售完成後公司已發行股本的約6.86%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.